Specifically, the growing mechanistic evidence of how the MAC modulates inflammation through activation of the inflammasome may lay the foundations for a broader application of anti-MAC therapies in the treatment of inflammatory diseases in which the complement system and IL-1β play an important role, including osteoarthritis, rheumatoid arthritis, and diseases of the central nervous system. Here, IL1B is linked to osteoarthritis.